logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Bupivacaine and meloxicam (HTX-011) for post-operative pain

< Back

Bupivacaine and meloxicam (HTX-011) for post-operative pain

Drugs

Anaesthetics, Pain Relief and ITU

October 2019


Bupivacaine and meloxicam (HTX-011) in a fixed-dose combination is in development for the management of post-operative pain. Post-operative pain is a typical example of acute pain. Acute pain typically lasts for less than 3-6 months (unlike chronic pain which carries on for longer than 12 weeks), and is provoked by identifiable stimuli and disappears as soon as the tissue injury or damage that had caused it is healed. All surgical procedures are associated with a certain level of post-operative pain. Opioids are often used to manage post-operative pain but carry the risk of harmful side effects, abuse and addiction.
In HTX-011, the inclusion of low-dose meloxicam reduces local inflammation and reverses the acidic environment caused by surgery, allowing enhanced penetration of bupivacaine (a local anaesthetic) into the nerves and thereby increasing its effect. HTX-011 is in development for application into the surgical site and early studies have shown its potential to reduce severe post-operative pain and the need for opioid analgesics for up to 72 hours. If licensed, HTX-011 may offer an additional treatment option for the management of post-operative pain with a potential to reduce the need for opioids.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts